These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Phase II study with methyl-6[[[2-chloroethyl) nitrosoamino] carbonyl] amino]-6-deoxy-alpha-D-glucopyranoside (MCNU) in hematological malignancies].
    Author: Masaoka T, Kimura K, Miyazaki T, Sakurada K, Saitoh H, Morioka M, Fujimoto N, Musashi M, Wakui A, Yokoyama M, Kanamaru R, Oguro M, Takagi T, Konda C, Saitoh T, Nakao I, Harashima S, Ohhashi Y, Sakai Y, Sasaki T, Ohno R, Katoh Y, Yamada K, Hirota Y, Takada T, Hoshino A, Ohara K, Kamiya O, Kojima T, Nagata K, Nakamura T, Sasada M, Yonezawa T, Tsubakio T, Kanayama Y, Kitani T, Taniguchi N, Yasunaga K, Okamoto Y, Fujitake H, Ohkubo A, Horiuchi A, Tsubaki K, Takubo T, Shibata H, Kawagoe H, Hirata M, Matsubuchi T, Nagai K, Fujita S.
    Journal: Gan To Kagaku Ryoho; 1983 Jun; 10(6):1518-23. PubMed ID: 6347081.
    Abstract:
    A total of 117 cases with hematological malignancies were treated with MCNU at doses of 70-100 mg/m2. Following are the results obtained. 1. MCNU showed a marked depression of cells in the cases with CML, polycythemia vera and thrombocythemia. The low level of cells was maintained for 2 to 7 months. 2. A good response was observed in several cases with blastic crises of CML. 3. No response was observed in two cases with acute leukemia. 4. Although a fair response was observed in several cases with malignant lymphoma or multiple myeloma, moderate bone marrow suppression was observed in a majority of the cases.
    [Abstract] [Full Text] [Related] [New Search]